Overall and complete response rates as potential surrogates for overall survival in relapsed/refractory multiple myeloma
Open Access
- 1 February 2023
- journal article
- review article
- Published by Taylor & Francis in Future Oncology
- Vol. 19 (6) , 463-471
Abstract
Aim: The correlation between response and survival has not been well-studied in relapsed or refractory multiple myeloma (RRMM). Materials & methods: A systematic literature review of Medline, Embas... Plain language summary Treatments for multiple myeloma may not work for every patient and the cancer may come back. In clinical trials, it is difficult to find out how well new treatments work in a... Tweetable abstract Potential surrogate? Overall response rate, very good partial response and duration of response were all shown to have a significant, moderate correlation with overall survival a...Keywords
Funding Information
- Pfizer
This publication has 26 references indexed in Scilit:
- Do Surrogate Endpoints Better Correlate with Overall Survival in Studies That Did Not Allow for Crossover or Reported Balanced Postprogression Treatments? An Application in Advanced Non–Small Cell Lung CancerValue in Health, 2018
- A question of class: Treatment options for patients with relapsed and/or refractory multiple myelomaCritical Reviews in Oncology/Hematology, 2018
- Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Patients with Relapsed or Refractory Multiple MyelomaValue in Health, 2017
- Multiple myelomaNature Reviews Disease Primers, 2017
- Relationship between response rates and median progression‐free survival in non‐Hodgkin's lymphoma: A meta‐analysis of published clinical trialsHematological Oncology, 2017
- Relationship between Treatment Effects on Progression-Free Survival and Overall Survival in Multiple Myeloma: A Systematic Review and Meta-Analysis of Published Clinical Trial DataOncology Research and Treatment, 2015
- IMWG consensus on risk stratification in multiple myelomaLeukemia, 2013
- Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' dataThe Lancet Oncology, 2013
- Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013Mayo Clinic Proceedings, 2013
- Understanding heterogeneity in meta-analysis: the role of meta-regressionInternational Journal Of Clinical Practice, 2009